Generation Bio Co. (NASDAQ:GBIO) Receives $8.88 Average Price Target from Analysts

Shares of Generation Bio Co. (NASDAQ:GBIO) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $8.8750.

A number of research firms have recently commented on GBIO. Citigroup reissued a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th. Wedbush set a $5.50 target price on shares of Generation Bio and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and lowered their price target for the company from $11.00 to $5.00 in a research report on Tuesday, December 16th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a research note on Friday, November 7th.

Generation Bio Price Performance

Shares of NASDAQ:GBIO opened at $5.65 on Friday. The stock has a market capitalization of $38.08 million, a P/E ratio of -0.60 and a beta of 2.05. The business has a 50-day moving average of $5.40 and a two-hundred day moving average of $5.40. Generation Bio has a fifty-two week low of $3.00 and a fifty-two week high of $10.40.

Generation Bio (NASDAQ:GBIO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $0.66 million. As a group, research analysts expect that Generation Bio will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GBIO. AQR Capital Management LLC bought a new stake in shares of Generation Bio in the first quarter valued at approximately $36,000. Marshall Wace LLP acquired a new position in Generation Bio during the 2nd quarter valued at $37,000. Y Intercept Hong Kong Ltd bought a new stake in Generation Bio in the 2nd quarter valued at $47,000. Shay Capital LLC bought a new stake in Generation Bio in the 3rd quarter valued at $64,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Generation Bio in the 3rd quarter worth $136,000. 95.22% of the stock is owned by institutional investors.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.